Technical Analysis for ONTX - Onconova Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.0 -6.98% -0.15
ONTX closed down 6.98 percent on Thursday, January 17, 2019, on 1.98 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ONTX trend table...

Date Alert Name Type % Chg
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Fell Below 20 DMA Bearish -6.98%
Jan 16 Volume Surge Other -6.98%
Jan 16 Wide Bands Range Expansion -6.98%
Jan 15 1,2,3 Retracement Bearish Bearish Swing Setup -15.25%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -15.25%
Jan 15 Crossed Above 20 DMA Bullish -15.25%
Jan 15 Pocket Pivot Bullish Swing Setup -15.25%
Jan 15 Spinning Top Other -15.25%
Jan 15 Volume Surge Other -15.25%

Older signals for ONTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company's products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Is ONTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.7
52 Week Low 1.69
Average Volume 101,759
200-Day Moving Average 6.067
50-Day Moving Average 3.3726
20-Day Moving Average 2.255
10-Day Moving Average 2.3415
Average True Range 0.3314
ADX 42.52
+DI 12.2812
-DI 27.1436
Chandelier Exit (Long, 3 ATRs ) 2.0558
Chandelier Exit (Short, 3 ATRs ) 2.6842
Upper Bollinger Band 2.7522
Lower Bollinger Band 1.7578
Percent B (%b) 0.24
BandWidth 44.097561
MACD Line -0.3178
MACD Signal Line -0.3756
MACD Histogram 0.0578
Fundamentals Value
Market Cap 19.7 Million
Num Shares 9.85 Million
EPS -2.57
Price-to-Earnings (P/E) Ratio -0.78
Price-to-Sales 9.36
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.47
Resistance 3 (R3) 2.49 2.37 2.39
Resistance 2 (R2) 2.37 2.25 2.35 2.36
Resistance 1 (R1) 2.18 2.18 2.12 2.16 2.34
Pivot Point 2.06 2.06 2.03 2.04 2.06
Support 1 (S1) 1.87 1.94 1.81 1.85 1.66
Support 2 (S2) 1.75 1.87 1.73 1.64
Support 3 (S3) 1.56 1.75 1.61
Support 4 (S4) 1.54